If You Invested in ANEW MEDICAL, INC. (WENA)

WENA historically represented ANEW MEDICAL, INC. on the Nasdaq Stock Market. According to company news and SEC filings, the business has since been renamed and now operates as Klotho Neurosciences, Inc. with the Nasdaq trading symbol KLTO and listed warrants under KLTOW. The company is described in its own disclosures as a biopharmaceutical and biotechnology company focused on the development of patented, disease‑modifying technologies targeting the brain and central nervous system (CNS), particularly for neurodegenerative and age‑related disorders.

Company news releases explain that Klotho Neurosciences (formerly ANEW Medical) concentrates on therapies based on the human Klotho gene, often referred to in their materials as an “anti‑aging gene.” The company has obtained exclusive worldwide rights and issued patents covering a secreted form of Klotho, known as s‑KL, and describes a platform of protein, gene, cell and peptide therapies aimed at conditions such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, rare neurodegenerative diseases and other age‑related pathologies.

Corporate evolution and ticker change

A company news release dated September 17, 2024 states that ANEW MEDICAL, INC. changed its name to Klotho Neurosciences, Inc. and that its Nasdaq ticker symbol changed from WENA to KLTO. The announcement notes that the name and ticker change did not alter existing shareholdings and that no action was required from shareholders. Subsequent SEC filings, including multiple Form 8‑K reports and a Form 12b‑25, identify the registrant as Klotho Neurosciences, Inc. with common stock trading under the symbol KLTO and warrants under KLTOW on the Nasdaq Stock Market.

Therapeutic focus on Klotho gene technology

Company disclosures emphasize a core investment focus on a patented, secreted form of the Klotho gene, s‑KL.> Through exclusive worldwide licenses, Klotho Neurosciences reports rights to platform technologies and know‑how to develop genetic approaches using protein, gene and cell therapies. These programs target neurodegenerative diseases and age‑related disorders, including ALS, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, rare neurodegenerative diseases, and conditions such as osteoporosis, sarcopenia, diabetes mellitus and certain cardiovascular disorders that the company associates with aging.

In several news releases, the company states that maintaining elevated levels of Klotho is associated in its research with longer, healthier lifespans, while depleted Klotho levels are associated with susceptibility to neurodegenerative and age‑related diseases. The company’s gene therapy program centers on the secreted Klotho isoform s‑KL, which it describes as an RNA splice variant primarily synthesized in the brain and essential for maintaining normal brain and neurological functions.

Pipeline areas and programs

Based on its own public statements, Klotho Neurosciences’ development activities span several areas within neurosciences and aging:

• Klotho gene therapy for neurodegenerative disorders: The company reports patents in Europe, China, Hong Kong and other Asian markets, and a U.S. patent covering a secreted RNA splice variant of the human Klotho gene (s‑KL) for the treatment of cognitive and neurodegenerative diseases. Its disclosures describe plans to advance gene therapy programs for ALS, Alzheimer’s disease, Parkinson’s disease and related disorders, using delivery systems such as adeno‑associated virus (AAV) vectors to deliver the s‑KL DNA sequence to neurons in the CNS.
• Healthy longevity and diagnostics: Company materials describe a goal of enhancing the potential for people to achieve healthy longevity. This includes the development of diagnostics to quantify Klotho gene and protein isoform levels in blood samples, which the company indicates could be used both to screen patients for clinical trials and to explore the role of Klotho in longevity and age‑related disease risk.
• Cell and gene‑based treatments for aging and age‑related diseases: News releases describe a broader focus on cell and gene‑based therapies for neurological and age‑related disorders, with an emphasis on CNS diseases, dementia symptoms and neuromuscular diseases.
• Peptide therapeutics for weight and eating disorders: The company reports a worldwide licensing agreement to develop proprietary peptides that selectively bind and activate melanocortin receptors on neuronal cells in the brain. According to its disclosures, these programs are aimed at eating disorders and weight‑related conditions such as obesity (overeating) and cachexia or sarcopenia, with the goal of developing orally administered peptide formulations.
• Nanoject needle‑free dry powder autoinjector: In an August 2024 news release, ANEW MEDICAL (now Klotho Neurosciences) announced an exclusive worldwide license for Nanoject, described as a needle‑free, freeze‑dried nanopowder autoinjector for medicines and vaccines. The company’s description states that Nanoject uses a pressure‑driven flow generated by a miniature shock tube to deliver nano‑ or micron‑sized particles of medicines, including drugs, proteins, DNA and RNA, into the skin for intradermal and subcutaneous delivery. The company characterizes this as part of its drug‑delivery assets, alongside its gene therapy and biologics programs.
• Antibody biologics programs: Company descriptions also mention clinical‑stage programs involving antibody biologics targeting cancer and autoimmune diseases as part of its broader portfolio.

Intellectual property and licensing

Multiple news releases detail the company’s intellectual property position. Klotho Neurosciences reports that its IP portfolio for Klotho‑based therapies has been licensed on an exclusive worldwide basis from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Barcelona, Spain. The company states that patents have been granted in Europe, China, Hong Kong and other Asian markets for the use of its Klotho protein and gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases.

Additional disclosures describe patents in major Asian markets, including China and Hong Kong, protecting the secreted form of human Klotho protein (s‑KL) and associated gene delivery systems for treating Alzheimer’s disease, ALS and other neurodegenerative diseases. The company characterizes the issuance of these patents as providing protection for development and commercialization in those territories.

Collaborations and research partnerships

Company announcements highlight a collaboration with the Okinawa Research Center for Longevity Science (ORCLS) in Japan and Hawaii. According to these disclosures, researchers at ORCLS have conducted long‑term studies of centenarians and healthy long‑lived individuals in Okinawa, described as a “Blue Zone.” Klotho Neurosciences reports that it is working with ORCLS to analyze stored blood samples from these individuals to assess Klotho and s‑KL levels and to better understand the relationship between Klotho expression, longevity and neurodegenerative disease risk.

The company also notes that this work is intended to help validate clinical assays for Klotho that may be used in future to identify people at higher risk for accelerated aging and neurological pathologies. In addition, the company has disclosed a licensing alliance with Transfertech Sherbrooke (TTS) and collaboration with an academic laboratory at the Université de Sherbrooke in connection with the Nanoject needle‑free autoinjector technology.

Regulatory and development milestones

SEC filings and company press releases indicate that Klotho Neurosciences is an emerging growth company under U.S. securities regulations and that its common stock and warrants are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Stock Market. A Form 8‑K filed in July 2025 reports that the U.S. Food and Drug Administration granted Orphan Drug Designation for the company’s gene therapy candidate KLTO‑202 for the treatment of ALS (Lou Gehrig’s disease. Another Form 8‑K filed in June 2025 refers to a press release about the commencement of manufacturing for a gene therapy candidate, and an August 2025 Form 8‑K describes a letter agreement with AAVnerGene Inc. for manufacturing and development of the KLTO‑202 gene therapy candidate using AAVnerGene’s platform technology.

A Form 12b‑25 (Notification of Late Filing) dated August 2025 identifies Klotho Neurosciences, Inc. as the registrant and explains that the company could not complete its Quarterly Report on Form 10‑Q for the period ended June 30, 2025 within the prescribed time because the financial statements and related review could not be completed in time. The filing states that the company expected to file the report within the permitted extension period and that no significant change in results of operations from the corresponding period of the prior year was anticipated for that report.

Financial structure and balance sheet actions

In an August 2024 news release, ANEW MEDICAL, INC. reported the successful conversion of its convertible promissory notes by investors, stating that this eliminated over $4 million in long‑term debt and removed related annual interest payments. The company characterized this as increasing stockholder equity and enhancing financial flexibility to pursue its research and development programs targeting age‑related diseases.

Management and governance

Company news and SEC filings refer to Klotho Neurosciences as being managed by a team of individuals and advisors described as highly experienced in biopharmaceutical and medical product development and commercialization. An August 2024 news release announced the appointment of a new Chief Financial Officer and described his prior experience in financial operations and investment roles. An amended Form 8‑K filed in July 2025 discusses the resignation of a former director associated with the company’s prior business combination and clarifies the effective date of that resignation.

Business model and sector classification

Across its disclosures, the company consistently describes itself as a biopharmaceutical or biotechnology company specializing in the advancement of novel, patented, disease‑modifying therapies and specialty diagnostics for neurological and age‑related disorders, with a strong emphasis on CNS diseases and gene‑ and cell‑based approaches. It also identifies itself as a technology and medical product development company in connection with its drug‑delivery and biologics assets.

Investors researching the historical WENA symbol should be aware that it now corresponds to Klotho Neurosciences, Inc. trading under KLTO on Nasdaq. The information summarized here is drawn from the company’s own news releases and SEC filings, which provide the primary source material on its business focus, intellectual property, collaborations and regulatory milestones.